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NEP-mediated pathway, it would appear that NEP fails to 
provide adequate surveillance of SP levels. Failure of NEP to 
overexpress could be associated with miRNA regulation.
 Copyright © 2012 S. Karger AG, Basel
 Introduction
 Chronic pancreatitis (CP) is an often painful inflam-
matory disease that leads to pancreatic insufficiency  [1, 
2] . The pathophysiology of pain, the main symptom in 
75% of patients with CP, is still poorly understood. First 
Keith et al.  [3]  and later Bockman et al.  [4]  suggested that 
neural and perineural alterations might modulate pain 
pathogenesis in CP. Further studies showed that levels of 
the growth-associated protein-43 (GAP-43), a well-estab-
lished marker of neuronal plasticity, as well as the neuro-
peptide substance P (SP) and its receptor neurokinin-1 
(NK-1R), significantly correlated with pain in CP patients 
 [5–8] . The neuropeptide SP is involved in neural trans-
mission of sensory information, smooth muscle contrac-
tion, and nociception, with a wide range of functional 
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 Abstract
 Background/Aims: We aimed to analyze substance P (SP) 
and neprilysin (NEP), the membrane metallopeptidase that 
degrades SP, in chronic pancreatitis (CP).  Methods: SP and 
NEP mRNA levels were analyzed by qRT-PCR in tissue sam-
ples from 30 patients with CP and 8 organ donors. In addi-
tion, SP serum levels were determined before and after sur-
gery in the same patients, by means of a competitive ELISA 
assay. Genetic and epigenetic analyses of the NEP gene were 
also performed.  Results: SP mRNA expression levels were 
higher in CP tissues compared to controls (p = 0.0152), while 
NEP mRNA showed no significant differences between CP 
and healthy subjects (p = 0.2102). In CP patients, SP serum 
levels correlated with those in tissue, and after surgical resec-
tion SP serum levels were reduced compared to the preop-
erative values. Failure of NEP to overexpress in CP tissues was 
associated with significant miR-128a overexpression (p = 
0.02), rather than with mutations in the NEP coding region or 
the presence of hypermethylation sites in the NEP promoter 
region.  Conclusion: Tissue and serum levels of SP were in-
creased in CP, while NEP levels remained unaltered. In an SP/
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effects, not only in the central and peripheral nervous 
systems, but also in the so-called ‘neuroimmune cross-
talk’ between the nervous and the immune systems  [9] . It 
is also known that the SP/NK-1R pathway is regulated by 
neprilysin (also known as neutral endopeptidase, NEP), 
a major membrane-bound metalloenzyme responsible 
for degrading SP in human tissues  [10] . Recently, Michal-
ski et al.  [11] showed that NEP levels were not increased 
in patients with CP. Therefore, evaluation of the possible 
mechanisms responsible for NEP gene regulation may be 
important for clarification of the SP-mediated pathway in 
CP. So far, gene promoter hypermethylation and micro-
RNA (miRNA, miR)-mediated regulation of gene expres-
sion represent two important mechanisms of gene silenc-
ing that might explain NEP disturbance in CP. As report-
ed by Usmani et al., hypermethylation of specific CpG 
islands was associated with the loss of NEP expression in 
prostate cancer  [12] . On the other hand, miRNAs repre-
sent a new class of noncoding RNA molecules of approx-
imately 22 nucleotides in length, which bind the 3  UTR 
of target mRNAs and mediate translational repression in 
animals. MiRNAs have been shown to regulate develop-
mental processes, such as self-renewal of stem cells and 
differentiation of cancer and neuronal cells  [13] . In par-
ticular, miR-128a was reported to play a central role in the 
nervous system since it was found to be enriched in the 
brain during neural cell differentiation and involved in 
neuronal differentiation and synaptic formation and 
plasticity  [14, 15] . Furthermore, in brain tissue from pa-
tients with Alzheimer’s disease, a direct correlation be-
tween miR-128 expression and down-regulation of NEP 
levels, the major amyloid-beta peptide catabolic enzyme, 
was observed  [16, 17] .
 In the present study we evaluated SP expression in CP 
to confirm that neuroimmune interaction is an impor-
tant factor in chronic inflammation of the pancreas. In 
addition, we investigated whether there is a relationship 
between SP levels in tissue and serum in patients with CP. 
NEP expression levels were also analyzed in order to eval-
uate the role of this enzyme in the SP-mediated pathway. 
Finally, we performed genetic and epigenetic analysis of 
the NEP gene and tested the possible involvement of spe-
cific miRNA in regulation of NEP gene expression.
 Patients and Methods
 Patient Population and Tissue Sampling
 Tissue samples were obtained from 30 patients (22 males, 8 fe-
males; median age 50 years, range 30–72) undergoing pancreatic 
resection for CP. The primary cause of CP was alcohol abuse in all 
patients. In all cases, the surgical procedure consisted of duode-
num-preserving pancreatic head resection performed for medi-
cally intractable recurrent abdominal pain. Normal human pan-
creatic tissue samples were obtained through an organ donor pro-
gram from 8 previously healthy individuals (5 males, 3 females; 
median age 43 years, range 35–60). In all cases, freshly removed 
tissue samples were fixed in paraformaldehyde solution for 12–
24  h, followed by paraffin embedding for histological analysis. 
Furthermore, part of the tissue samples destined for RNA extrac-
tion and for protein extraction was frozen in liquid nitrogen im-
mediately upon surgical removal and maintained at –80   °   C. In ad-
dition, blood samples were collected from CP patients on the day 
prior to surgery and on day 3 postoperatively. This early measure-
ment of SP serum level was performed to evaluate the immediate 
variation in the level of this neuropeptide after the removal of the 
head of the pancreas. Blood samples from 8 healthy individuals 
were also collected to obtain the normal value of SP serum levels. 
Samples were allowed to clot for 30 min before centrifugation for 
10 min at 1,000  g , and then serum samples were transferred to new 
plastic tubes and stored at –80   °   C until evaluated for SP levels. 
 The present study excluded patients with medical histories of 
other chronic inflammatory diseases (asthma, rheumatoid ar-
thritis), or major depression. The study was approved by the eth-
ics committees of the University of Heidelberg, Heidelberg, Ger-
many (No. 301/01), and Hospital Casa Sollievo della Sofferenza, 
San Giovanni Rotondo, Italy (No. 8450/08). 
 Quantitative RT-PCR
 All reagents and equipment for mRNA and cDNA preparation 
were purchased from Roche (Roche Applied Science, Mannheim, 
Germany). RNA was prepared by automated isolation using the 
MagNA Pure LC instrument and isolation kit (specific for tis-
sues). RNA was reverse transcribed into cDNA using the First 
Strand cDNA synthesis kit, according to the manufacturer’s in-
structions. 
 Real-time qRT-PCR was performed with the Light Cycler Fast 
Start DNA SYBR Green kit, as described previously  [18, 19] . The 
standard curve method is used to assess the amount of SP and 
NEP mRNA, and expression values were normalized to the house-
keeping genes cyclophilin B and hypoxanthine-guanine phos-
phoribosyltransferase. All primers were obtained from Search-
LC (Heidelberg, Germany).
 Enzyme-Linked Immunosorbent Assay
 The quantitative measurement of SP in serum was determined 
using a commercially available ELISA kit (R&D Systems Inc., 
Minneapolis, Minn., USA), following the standard conditions 
recommended by the manufacturer. This immunoassay is based 
on the competitive binding technique, in which SP present in a 
sample competes with a fixed amount of alkaline phosphatase-
labeled SP for sites on a rabbit polyclonal antibody. Immediately 
following color development, the absorbance is read at 405 nm. 
The sensitivity of the SP assay is less than 8.0 pg/ml.
 NEP Coding Region Analysis
 Primers were designed, using the Primer 3 program, to spe-
cifically amplify the entire Open Reading Frame of the NEP gene 
(RefSeq accession No. NM_000902). The PCR reaction was run 
on each exon with a total sample volume of 25   l containing 50–
100 ng of DNA, 0.10   M of each respective primer, 0.25 m M of each 
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dNTP, 1 ! buffer, and 1 U of AmpliTaq Gold  DNA Polymerase 
(PE Applied Biosystems, Foster City, Calif., USA). The PCR am-
plification was performed with an initial denaturing step at 95   °   C 
for 10 min, followed by 35 cycles consisting of denaturation at 
94   °   C for 30 s, annealing at melting temperature for 30 s, extension 
at 72   °   C for 30 s, and ending with a final extension step at 72   °   C 
for 7 min. PCR products were checked on 2% agarose/TBE gels 
and were purified using Illustra TM  GFX PCR and Gel Purification 
Kit (GE Healthcare Life Sciences, Buckinghamshire, UK) to re-
move unused primers and precursors according to the manufac-
turer’s instructions.
 Amplicons were then screened for sequence variants by dena-
turing high-performance liquid chromatography (DHPLC) on a 
WAVE DNA fragment analysis system (Transgenomic, San Jose, 
Calif., USA) according to the manufacturer’s protocol. The run-
ning conditions for each amplicon were determined by the Wave-
maker 3.4.4 software (Transgenomic) based on the DNA se-
quence. PCR product was denatured by heating it to 94    °    C for 
5 min, followed by cooling to 50   °   C over a 25-min period to en-
hance heteroduplex formation. DHPLC variants displaying vari-
ant elution peaks were confirmed by direct sequencing with the 
Big Dye TM  terminator cycle sequencing ready reaction kit (Ap-
plied Biosystems, Inc., Foster City, Calif., USA) on an ABI Prism TM  
3100 DNA Sequencer under the standard conditions recommend-
ed by the manufacturer. Sequences obtained were aligned and 
compared to wild-type sequences using AB Navigator Analysis 
Software (PE Applied Biosystems).
 NEP Promoter Methylation Assay
 Two CpG islands (NEP-Met1 and NEP-Met2) were identified 
in the promoter region of the candidate NEP gene using the UCSC 
genome browser (http://genome.ucsc.edu/). Specific primers were 
designed on the sense filament of the NEP promoter gene using 
the MethPrimer Software (http://www.urogene.org/methprim-
er/) ( table 1 ).
 First, 1–2   g of DNA was chemically treated using the Epitect 
Bisulfite Kit (Qiagen, GmbH, Germany) following the manufac-
turer’s protocol. This bisulfite-converted DNA was amplified for 
the housekeeping   -actin  (ACTB) gene to estimate the efficiency 
of chemical modification. Then, one-step methylation-specific 
PCRs (MSPs) were performed to specifically amplify bisulfite-
converted sequences of NEP-Met1 and NEP-Met2. The PCR reac-
tion was run in a total sample volume of 20   l containing 50–100 
ng of bisulfite-modified DNA using Platinum Taq DNA Poly-
merase (Invitrogen TM , Carlsbad, Calif., USA) according to the 
manufacturer’s instructions, and amplification was performed 
following the touch-down PCR method. MSP products were vi-
sualized in a 2% agarose/TBE gel. Each MSP was repeated in trip-
licate, with each assay including both water blanks and in vitro 
methylated DNA as positive controls for the methylation status of 
DNA. This positive control was obtained by treating the DNA 
from lymphocytes of healthy volunteers with  Sss I methyltransfer-
ase (New England Biolabs, Beverly, Mass., USA) according to the 
manufacturer’s instructions and based on the results of previous 
studies  [20] .
 miRNA Expression Analysis
 We selected the miR-128a gene from mirBase using the
Sanger Center miRNA Registry (http://microrna.sanger.ac.uk/
sequences/index.shtml). mirBase is one of the most well-known 
target prediction databases, and it identifies NEP as a specific 
miR-128a target.
 MiRNAs were isolated from fresh pancreatic tissues of CP pa-
tients (n = 13) and healthy donors (n = 8) using TRIzol  reagent 
(Invitrogen) according to the manufacturer’s instructions. 
 TaqMan MicroRNA Assay for miR-128a, available through 
Applied Biosystems (P/C: 4395327, Applied Biosystems), was used 
for quantitative determination of mature miR-128a using the 
standard curve method, and expression values were normalized 
to the endogenous control U6B small nuclear RNA (RNU6B) 
(P/C: 4373381, Applied Biosystems). TaqMan MicroRNA TM  As-
says include RT and real-time PCR with only two steps. Therefore, 
10 ng of total RNA was first reverse transcribed into cDNA with 
a final reaction volume of 15   l using the TaqMan MicroRNA 
Reverse Transcription Kit (P/N: 4366596, Applied Biosystems) 
and a 5 ! specific stem-loop RT primer (P/N: 4395327 and 
4373381, Applied Biosystems) according to the manufacturer’s in-
structions. Next, PCR reactions were assembled with a final reac-
tion volume of 10   l (using 384-well plates), using 20 ! TaqMan 
Assay (P/N: 4395327 and 4373381, Applied Biosystems) and Uni-
versal MasterMix without UNG (P/N: 4324018, Applied Biosys-
tems) according to the manufacturer’s instructions. Real-time 
PCR was performed with an Applied Biosystems 7900HT Se-
quence Detection System, using FAM TM  dye as the reporter. All 
reactions, including a no-template control and the RT negative 
control, were run in triplicate, and the average Ct values were used 
to perform subsequent analyses, discarding any outliers ( 1 2 stan-
dard deviations).
 Statistical Analysis
 Results are expressed as mean  8 SD. Statistical analysis was 
carried out using the software GraphPad (Prism, Inc., San Diego, 
Calif., USA). The comparative statistical evaluations among 
groups were done using the Mann-Whitney U test. Correlation 
analysis was performed using the Pearson correlation coefficient. 
A p  ! 0.05 was considered statistically significant. 
 Table 1. Details of the CpG islands within the NEP promoter region (total length: 1,847 bp) and forward and reverse primer sequenc-
es for methylation-specific PCRs of NEP-Met1 and NEP-Met2 CpG islands
 CpG island  Size  Start–end  Forward oligonucleotide sequence (5  –3  )  Reverse oligonucleotide sequence (5  –3  ) 
 NEP- Met1  137 bp  971–1110  GGTTTTGTAGCGGCGAGGCGGG  TCCCGCGCCAAAAATTAAACGAC 
 NEP-Met2  157 bp  1163–1320  AGGTGTTTCGTCGTTTTACGG  TAAACGCACGAAACCGAATAAC 
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 Results
 Quantitative RT-PCR
 SP mRNA expression levels ranged from 6 to 55 
copies/  l (mean = 24.75, SD = 16.184 copies/  l) in nor-
mal pancreas samples, while a larger detectable range 
from 0 to 452 copies/  l (mean = 94.06, SD = 117.536 
copies/  l) was observed in CP tissues. Looking at SP 
mRNA expression in CP patients compared to normal 
controls, we observed that SP levels were significantly 
higher in CP than in normal tissue samples (p = 0.0152) 
( fig. 1 a). Conversely, no significant differences were ob-
served in NEP mRNA expression levels between CP 
(range = 0–233, mean = 55, SD = 62 copies/  l) and nor-
mal samples (range = 0–75, mean = 26.5, SD = 26 
copies/  l; p = 0.2102) ( fig.  1 b). Correlation analysis 
showed no significant linear association between SP and 
NEP expression levels among the 30 CP tissue samples (r 
= 0.03, p = 0.015). Therefore, the mean level of SP mRNA 
in control groups was used as a cutoff value to distin-
guish patients with high SP levels from those with low 
expression of SP. Similarly, the mean NEP mRNA level 
observed in healthy subjects was used as a cutoff value to 
separate patients with high NEP expression from those 
with low NEP levels. Correlation analysis, performed in 
the subgroups of samples with low NEP mRNA and high 
SP mRNA expression levels, showed a significant inverse 
correlation between NEP and SP expression levels (r = 
–0.96, p  ! 0.01). 
 Enzyme-Linked Immunosorbent Assay
 In normal subjects, SP serum levels ranged from 35 to 
91 pg/ml (mean = 59.62, SD = 22.803 pg/ml). Preopera-
tive SP serum levels were increased in 80% (24/30) of CP 
patients compared to normal controls (range = 10–1,182, 
mean = 222.23, SD = 237.637 pg/ml). Interestingly, SP 
serum levels observed in CP patients were 4 times higher 
than those in normal subjects (p = 0.0058) ( fig. 2 a).
 In addition, 58% (14/24) of patients with elevated pre-
operative SP serum levels (range = 139–561, mean = 270.5, 
SD = 140.3 pg/ml) exhibited a significant decrease in SP 
serum level 3 days after surgery (range = 64–421, mean = 
185.1, SD = 125.9 pg/ml; p = 0.0416) ( fig. 2 b). 
 Screening of NEP Coding Region
 Screening of the NEP coding region did not reveal any 
mutation of interest; it revealed only the presence of 7 in-
tronic polymorphisms located downstream or upstream 
of several exons ( fig. 3 ). In particular, 2 of these 7 intron-
ic polymorphisms were located 28 bases downstream of 
exon 4 (c.439 + 28G 1 T) and 20 bases downstream of exon 
14 (c.1497 + 20A 1 G), respectively, and were observed 
only in 1 patient. They were not present in donors and had 
not been described before. 
 NEP Promoter Methylation Assay
 This analysis was performed only in the subgroup of 
CP patients (n = 13) with SP mRNA levels higher than 
those in healthy controls (n = 8), since in these patients 
we expected to find a failure in NEP gene expression.
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 Amplification of the  ACTB housekeeping gene under-
lined a good efficiency of sodium-bisulfite modification 
( fig. 4 a). However, the methylation status of both NEP-
Met1 and NEP-Met2 islands was substantially unchanged 
in CP samples compared to healthy donors ( fig. 4 b, c).
 miR-128a Expression Analysis
 As for the NEP promoter methylation assay, this anal-
ysis was performed only in the subgroup of CP patients 
with increased SP expression levels (n = 13) compared to 
the group of healthy donors (n = 8). 
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 Expression levels of mature miR-128a ranged from 478 
to 3,085 copies/  l in healthy donor samples (mean = 
1,990, SD = 5,496 copies/  l) and from 678 to 21,128 
copies/  l in tissues from CP patients (mean = 6,386, 
SD = 888 copies/  l). Interestingly, miR-128a expression 
levels were significantly higher in CP samples than in 
samples from healthy donors (p = 0.02) ( fig. 5 ). Further-
more, miR-128a values were evaluated in correlation with 
both NEP and SP mRNA expression levels. Interestingly, 
we found that miR-128a was negatively correlated to NEP 
expression levels (r = –0.8, p = 0.016), while a direct as-
sociation between miR-128a and SP mRNA (r = 0.9, p  ! 
0.01) was observed in CP tissue samples.
 Discussion
 Over the past decades, evidence has been obtained re-
garding the interactions between the immune and ner-
vous systems. Proinflammatory neuropeptides, released 
from central and peripheral nerve fibers, can modulate 
the chronic inflammation response by activating the im-
mune cells, such as macrophages, lymphocytes, and neu-
trophiles  [21] . This response plays a role in many inflam-
matory conditions, such as chronic appendicitis  [9] , ul-
cerative colitis, and Crohn’s disease  [21] , as well as asthma 
and arthritis  [22] . 
 In the present study we focused on the SP-mediated 
pathway in CP. Expression levels of SP and NEP were an-
alyzed in tissue samples from patients undergoing pan-
creatic resection due to painful CP. Our results confirmed 
that SP mRNA levels were increased in CP tissues com-
pared to normal controls, suggesting that SP can be syn-
thesized not only outside of the pancreas by extrapancre-
atic ganglia but also by immune cells present in the in-
flamed pancreatic tissues  [23] . Interestingly, analysis of 
preoperative SP serum levels showed a significant in-
crease in SP patients compared to normal subjects. Three 
days after pancreatic resection, following removal of the 
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ACTB amplification underlined the effi-
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pain trigger, 58% of the patients exhibited a significant 
reduction in SP serum levels. In addition, there was a sig-
nificant inverse correlation between SP and NEP mRNA 
levels in a subgroup of CP tissue samples. These data al-
low us to hypothesize that NEP might fail to provide ad-
equate surveillance of SP levels. Indeed, in the absence of 
this degrading enzyme, accumulation of SP can take 
place, and in turn sustain inflammation and pain ( fig. 6 ). 
Looking at different mechanisms for NEP gene regula-
tion, we performed both genetic and epigenetic analysis 
in order to identify possible mutations and/or potential 
sites of hypermethylation in the promoter region. How-
ever, no mutation was found in the NEP gene coding re-
gion, and MSP analysis showed that methylation status
of NEP-Met1 and NEP-Met2 islands was substantially 
unchanged in CP samples when compared with samples 
of healthy donors. Thus we considered the possibility
of miRNA-mediated post-transcriptional regulation of 
NEP gene expression. Genes with long 3  UTRs are more 
prone to miRNA-mediated regulation than genes with 
short 3  UTRs, which tend to be specifically deprived of 
miRNA target sites  [24] . Interestingly, the full-length 
NEP transcript includes a long 3  UTR region of 3,270 
bases (information obtained from http://genome.ucsc.
edu/) suitable to be targeted by specific miRNAs. miR-
128a was selected from the Sanger Center miRNA Regis-
try and based on all the available evidence on this miRNA 
reported in the literature  [16, 17, 25, 26] . Interestingly, in 
tissues from CP patients with high SP amounts and no 
increase in NEP expression levels, we found significant 
overexpression of miR-128a compared to tissues from 
normal controls. In addition, we observed that miR-128a 
levels were significantly correlated to both SP and NEP 
expression levels.
NEP mRNA levels
SP
NK-1R NK-1R
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Cell membrane Cell membrane
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
 
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 Fig. 6. Hypothetical model of SP, NEP and miR-128a involvement in CP. 
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 These data allow us to hypothesize for the first time 
that NEP expression might be associated with miRNA 
deregulation. Although this hypothesis may be consid-
ered speculative in the absence of functional studies, we 
can at least suppose that miR-128a plays a role in the 
modulation of the SP/NEP-mediated pathway ( fig.  6 ). 
Further studies are needed on this topic. Understanding 
the pathophysiology of pain generation and inflamma-
tion in CP could highlight new strategies for pain treat-
ment in CP patients, and could help us to select the best 
surgical procedure for these patients, with significant re-
percussions on the economic management and quality of 
life of these patients.
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